{
    "info": {
        "nct_id": "NCT04853576",
        "official_title": "A Phase 1/2 Study to Evaluate the Safety and Efficacy of a Single Dose of Autologous Clustered Regularly Interspaced Short Palindromic Repeats Gene-edited CD34+ Human Hematopoietic Stem and Progenitor Cells (EDIT-301) in Subjects With Severe Sickle Cell Disease",
        "inclusion_criteria": "Diagnosis of severe sickle cell disease as defined by:\n\n* Documented SCD genotype (βS/βS, βS/β0, βS/β+, or others) and\n* History of at least two severe vaso-occlusive events per year requiring medical attention despite hydroxyurea or other supportive care measures in the two year-period prior to provision of informed consent or assent, as applicable\n\nKarnofsky (for subjects >16 years of age) or Lansky (for subjects ≤ 16 years of age) Performance Status ≥ 80%\n\nNormal transcranial doppler velocity in subjects 16 years of age or younger\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 12 Years\nMust have maximum age of 50 Years",
        "exclusion_criteria": "* Available 10/10 HLA-matched related donor\n* Prior HSCT or contraindications to autologous HSCT\n* Any contraindications to the use of plerixafor during the mobilization of hematopoietic stem cells (HSCs) and any contraindications to the use of busulfan and any other medicinal products required during the myeloablative conditioning, including hypersensitivity to the active substances or to any of the excipients\n* Unable to receive red blood cell (RBC) transfusion for any reason\n* Unable or unwilling to comply with standard of care changes in background medical treatment in preparation of, during, or following HSCT, including and not limited to discontinuation of hydroxyurea, voxelotor, crizanlizumab, or L-glutamine\n* Any history of severe cerebral vasculopathy\n* Inadequate end organ function\n* Advanced liver disease\n* Any prior or current malignancy or immunodeficiency disorder\n* Immediate family member with a known or suspected Familial Cancer Syndrome\n* Clinically significant and active bacterial, viral, fungal, or parasitic infection\n\nOther protocol defined inclusion/exclusion criteria may apply",
        "miscellaneous_criteria": "Key"
    },
    "inclusion_lines": [
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Karnofsky (for subjects >16 years of age) or Lansky (for subjects ≤ 16 years of age) Performance Status ≥ 80%",
            "criterions": [
                {
                    "exact_snippets": "Karnofsky (for subjects >16 years of age) ... Performance Status ≥ 80%",
                    "criterion": "Karnofsky Performance Status",
                    "requirements": [
                        {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": ">",
                                "value": 16,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": ">=",
                                "value": 80,
                                "unit": "%"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Lansky (for subjects ≤ 16 years of age) ... Performance Status ≥ 80%",
                    "criterion": "Lansky Performance Status",
                    "requirements": [
                        {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": "<=",
                                "value": 16,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": ">=",
                                "value": 80,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of at least two severe vaso-occlusive events per year requiring medical attention despite hydroxyurea or other supportive care measures in the two year-period prior to provision of informed consent or assent, as applicable",
            "criterions": [
                {
                    "exact_snippets": "History of at least two severe vaso-occlusive events per year requiring medical attention despite hydroxyurea or other supportive care measures in the two year-period prior to provision of informed consent or assent",
                    "criterion": "severe vaso-occlusive events",
                    "requirements": [
                        {
                            "requirement_type": "frequency",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 2,
                                        "unit": "per year"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        },
                        {
                            "requirement_type": "medical attention required",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "despite hydroxyurea or other supportive care measures",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time period",
                            "expected_value": "in the two year-period prior to provision of informed consent or assent"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Key",
            "criterions": [
                {
                    "exact_snippets": "Key",
                    "criterion": "key status",
                    "requirements": [
                        {
                            "requirement_type": "N/A",
                            "expected_value": "Key"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have maximum age of 50 Years",
            "criterions": [
                {
                    "exact_snippets": "maximum age of 50 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "maximum",
                            "expected_value": {
                                "operator": "<=",
                                "value": 50,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 12 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 12 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Diagnosis of severe sickle cell disease as defined by:",
            "criterions": [
                {
                    "exact_snippets": "Diagnosis of severe sickle cell disease",
                    "criterion": "sickle cell disease",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Documented SCD genotype (βS/βS, βS/β0, βS/β+, or others) and",
            "criterions": [
                {
                    "exact_snippets": "Documented SCD genotype (βS/βS, βS/β0, βS/β+, or others)",
                    "criterion": "SCD genotype",
                    "requirements": [
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "genotype",
                            "expected_value": [
                                "βS/βS",
                                "βS/β0",
                                "βS/β+",
                                "others"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "Normal transcranial doppler velocity in subjects 16 years of age or younger",
            "criterions": [
                {
                    "exact_snippets": "Normal transcranial doppler velocity",
                    "criterion": "transcranial doppler velocity",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "normal"
                        }
                    ]
                },
                {
                    "exact_snippets": "subjects 16 years of age or younger",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "maximum",
                            "expected_value": {
                                "operator": "<=",
                                "value": 16,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Prior HSCT or contraindications to autologous HSCT",
            "criterions": [
                {
                    "exact_snippets": "Prior HSCT",
                    "criterion": "history of HSCT",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "contraindications to autologous HSCT",
                    "criterion": "contraindications to autologous HSCT",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Unable to receive red blood cell (RBC) transfusion for any reason",
            "criterions": [
                {
                    "exact_snippets": "Unable to receive red blood cell (RBC) transfusion for any reason",
                    "criterion": "red blood cell (RBC) transfusion",
                    "requirements": [
                        {
                            "requirement_type": "ability to receive",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Inadequate end organ function",
            "criterions": [
                {
                    "exact_snippets": "Inadequate end organ function",
                    "criterion": "end organ function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Clinically significant and active bacterial, viral, fungal, or parasitic infection",
            "criterions": [
                {
                    "exact_snippets": "Clinically significant and active bacterial ... infection",
                    "criterion": "bacterial infection",
                    "requirements": [
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Clinically significant and active ... viral ... infection",
                    "criterion": "viral infection",
                    "requirements": [
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Clinically significant and active ... fungal ... infection",
                    "criterion": "fungal infection",
                    "requirements": [
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Clinically significant and active ... parasitic infection",
                    "criterion": "parasitic infection",
                    "requirements": [
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any contraindications to the use of plerixafor during the mobilization of hematopoietic stem cells (HSCs) and any contraindications to the use of busulfan and any other medicinal products required during the myeloablative conditioning, including hypersensitivity to the active substances or to any of the excipients",
            "criterions": [
                {
                    "exact_snippets": "Any contraindications to the use of plerixafor during the mobilization of hematopoietic stem cells (HSCs)",
                    "criterion": "contraindications to plerixafor",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "any contraindications to the use of busulfan",
                    "criterion": "contraindications to busulfan",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "any contraindications to the use of ... any other medicinal products required during the myeloablative conditioning",
                    "criterion": "contraindications to other medicinal products required during myeloablative conditioning",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "including hypersensitivity to the active substances or to any of the excipients",
                    "criterion": "hypersensitivity to active substances or excipients",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any prior or current malignancy or immunodeficiency disorder",
            "criterions": [
                {
                    "exact_snippets": "Any prior or current malignancy",
                    "criterion": "malignancy",
                    "requirements": [
                        {
                            "requirement_type": "history or presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Any prior or current ... immunodeficiency disorder",
                    "criterion": "immunodeficiency disorder",
                    "requirements": [
                        {
                            "requirement_type": "history or presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Other protocol defined inclusion/exclusion criteria may apply",
            "criterions": [
                {
                    "exact_snippets": "Other protocol defined inclusion/exclusion criteria may apply",
                    "criterion": "other protocol defined inclusion/exclusion criteria",
                    "requirements": [
                        {
                            "requirement_type": "applicability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Unable or unwilling to comply with standard of care changes in background medical treatment in preparation of, during, or following HSCT, including and not limited to discontinuation of hydroxyurea, voxelotor, crizanlizumab, or L-glutamine",
            "criterions": [
                {
                    "exact_snippets": "Unable or unwilling to comply with standard of care changes in background medical treatment in preparation of, during, or following HSCT",
                    "criterion": "compliance with standard of care changes in background medical treatment",
                    "requirements": [
                        {
                            "requirement_type": "compliance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "discontinuation of hydroxyurea, voxelotor, crizanlizumab, or L-glutamine",
                    "criterion": "discontinuation of hydroxyurea, voxelotor, crizanlizumab, or L-glutamine",
                    "requirements": [
                        {
                            "requirement_type": "compliance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Available 10/10 HLA-matched related donor",
            "criterions": [
                {
                    "exact_snippets": "Available 10/10 HLA-matched related donor",
                    "criterion": "HLA-matched related donor",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "HLA match",
                            "expected_value": {
                                "operator": "=",
                                "value": 10,
                                "unit": "out of 10"
                            }
                        },
                        {
                            "requirement_type": "relationship",
                            "expected_value": "related"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Immediate family member with a known or suspected Familial Cancer Syndrome",
            "criterions": [
                {
                    "exact_snippets": "Immediate family member with a known or suspected Familial Cancer Syndrome",
                    "criterion": "immediate family member familial cancer syndrome status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "known",
                                "suspected"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any history of severe cerebral vasculopathy",
            "criterions": [
                {
                    "exact_snippets": "Any history of severe cerebral vasculopathy",
                    "criterion": "severe cerebral vasculopathy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Advanced liver disease",
            "criterions": [
                {
                    "exact_snippets": "Advanced liver disease",
                    "criterion": "liver disease",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "advanced"
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [
        {
            "line": "Key",
            "criterions": [
                {
                    "exact_snippets": "Key",
                    "criterion": "key eligibility criteria",
                    "requirements": [
                        {
                            "requirement_type": "N/A",
                            "expected_value": "N/A"
                        }
                    ]
                }
            ]
        }
    ],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}